Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 13/20 | 0.40 |
| ▸ | KRAS | P01116 | 12/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22862686 | 0.81 | EGFR (0.50) | SOS1KRASHTTKDM4ETSHR | |
| SCHEMBL29490225 | 0.81 | EGFR (0.50) | SOS1KRASHTTKDM4ETSHR | |
| SCHEMBL24704630 | 0.73 | MIF (0.37) | SOS1KRASPDE2A | |
| SCHEMBL24175234 | 0.72 | EGFR (0.36) | KDM4ETSHREGFRMEN1KMT2A | |
| SCHEMBL22862575 | 0.68 | EGFR (0.37) | SOS1KRASHTTKDM4ETSHR | |
| SCHEMBL29490242 | 0.68 | EGFR (0.37) | SOS1KRASHTTKDM4ETSHR | |
| SCHEMBL24159538 | 0.68 | KDM4E (0.36) | KDM4ETSHREGFRMEN1MAPT | |
| SCHEMBL22862611 | 0.68 | EGFR (0.50) | SOS1KRASHTTKDM4ETSHR | |
| SCHEMBL29490232 | 0.68 | EGFR (0.50) | SOS1KRASHTTKDM4ETSHR | |
| SCHEMBL22862964 | 0.68 | EGFR (0.50) | SOS1KRASHTTKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | BAX, TMBIM6, BCL2 | SOS1 1949/4885KRAS 77/4885HTT 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.